{
  "file_name": "27375577.pdf",
  "sections": {
    "general": "VP OF BUSINESS DEVELOPMENT\nProfessional Overview\nAccomplished Business Development executive with 7 years of experienceÂ in life science startups and clinical research organizations. I also have\nan entrepreneurial spirit as the co-founder of data analyticsÂ company, and a financial background through my Master's at Bentley University.Â",
    "education": "December 2012\nFinance McCallum Graduate School at Bentley University Finance Extensive case-based exercises in capital budgeting, corporate finance,\nmarketing sizing, equities, bonds, common financial covenants, and options. Experience in valuations including risk-adjusted net present value using\nWACC and CAPM and comparables\nMay 2011\nBachelor of Science : Economics & Finance Bentley University Cum Laude Economics & Finance",
    "experience": "01/2016 to Current\nVP of Business Development Company Name ï¼​ City , State\nPainQx (PQX) is a diagnostic/software company that developed a next generation approach to objectively measure pain in humans by\ndecoding neural activity.\nIncorporated the PQX platform in six clinical trials to be used as a pain biomarker to gauge the efficacy of experimental therapeutics.\nRaised $500k from angel groups and venture funds.\nIdentified a joint venture partner in China leading to a $1M investment.\nDeveloped an economic model demonstrating that the PQX technology reduces costs to health care providers by converting poorly\nmanaged pain patients to well-managed pain patients, saving up to $8,500 per patient.\nCreated financials statements including an income statement, balance sheet, and cash flow to justify capital raise and share with investors.\nCentralized contacts, alliances, and investors into a CRM system streamlining the business development.\nDeveloped all investor facing and business development presentations.\nFormed a strategic alliance with Evoke Neurosciences to incorporate their EEG headset into the PainQx platform providing a turnkey\nsolution to clinical research sponsors.\nCoordinated bottoms upmarket survey that interviewed 100 physicians to validate the PainQx value proposition and identify new markets\nfor the platform.\nSourced, pitched and won a grant by the National Institue on Drug Abuse (NIDA) recognizing PainQx as one of 10 companies national that\ncould address the opioid epidemic.\nPut together a SBIR Fast Track Application to be reviewed by NIDA.\n06/2012 to 01/2016\nCo-Founder VP of Business Development Company Name ï¼​ City , State\nLSN tracks the funding and partnering preferences of 5,000 investors and strategic partners by actively interviewing them on a 90-day\nrolling cycle.\nThis information allows entrepreneurs to identify investors and strategic that meet their fundraising and partnering needs.\nSince inception LSN has generated $4M in revenue, with 2016 revenue of $3M.\nIn 2015, LSN launched a broker-dealer, Boston Innovation Capital, to execute fundraising campaigns between $5M - $20M.\nOversee all aspects of operation such as sales, financial projections, IT, management, and marketing.\nGrew the LSN team to 22 employees: 7 business development representatives, 6 researchers, 4 conference representatives, and 2\nmarketers.\nCreated pitch decks, executive summaries, and websites for twelve biotech/medtech companies, resulting in increased investor\nresponsiveness.\nUtilize SalesForce.com to host LSN's back end data and linked it with an established graphical user interface, saving over $1M in R&D\ncosts.\nDeep knowledge of database and information systems including profile structuring, data segmentation and aggregation, and filtering.\nPersonally sourced, pitched, and closed over $1M in consulting and data services from Big Pharma, CROs, and emerging biotech/medtech\ncompanies.\nHelped create fundraising strategy for thirty-four biotech/medtech companies including EIP Pharma, Hsiri Therapeutics and JB Therapeutics\n(Corbus Pharma).\nBuilt personal network of over 1,000 life science investors, life science entrepreneurs, investment banks, family offices, and big\npharma/med-tech executives.\n02/2011 to 07/2012\nAbpro specializes in the generation of custom monoclonal antibodies. The foundation of Abpro's techn Company Name ï¼​ City , State\nAbpro specializes in the generation of custom monoclonal antibodies. The foundation of Abpro's technology is the HTP platform, a\ngenetically engineered mouse with a boosted immune system, enabling the mouse to have a broader epitope spread facilitating the generation\nof antibodies to traditionally difficult targets such as GPCR's, and 100% homologous target.\nPersonally closed $1.6M in new business revenue.\nPart of a business development team that grew sales from $700,000 in 2010, to $2.2M in 2011, and $4.0M in 2012.\nParticipated in a financing campaign that aimed to raise $3.4M in debt from various banks and mezzanine debt funds.\nModeled the present value of debt based offerings to provide investment decisions to upper management.\nDeveloped the company's first financial model that tied together income, balance sheet and cash flow statements.\nThis model was used to plan the future financing needs as well as develop the company's long-term budgetary constraints.\nBuilt and implemented an inventory tracking system to streamline operations leading to a 30% reduction in production delays.\nCreated an automated system that crawled three-hundred scientific journals gathering contact information of authors.\nThis information led to the creation of database of 100,000 contacts for use as a targeted email campaign.",
    "interests": "USA (14 years), London (6 years), Colombia (5 years), China (2 years).",
    "languages": "Native Speaker in English and Spanish",
    "skills": "streamline, approach, balance sheet, bonds, budgeting, business development, cash flow, clinical research, clinical trials, com, consulting, corporate\nfinance, CRM, database, email, English, equities, Fast, financials, financing, financial, fundraising, funds, graphical user interface, information\nsystems, Innovation, inventory, marketing, network, neural, next, presentations, Speaker, sales, scientific, Spanish, strategy, strategic, websites\nAdditional Information\nInternational Experience: USA (14 years), London (6 years), Colombia (5 years), China (2 years)."
  }
}